Hypertension in Cardiovascular and Kidney Disease: Recent Trends - Treating Two Diseases as One.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiorenal Medicine Pub Date : 2024-01-01 Epub Date: 2024-10-07 DOI:10.1159/000541876
Antonio De Pascalis, Alessandro Tomassetti, Daniele Vetrano, Edoardo Tringali, Luca Di Lullo, Marcello Napoli, Gaetano La Manna, Giuseppe Cianciolo
{"title":"Hypertension in Cardiovascular and Kidney Disease: Recent Trends - Treating Two Diseases as One.","authors":"Antonio De Pascalis, Alessandro Tomassetti, Daniele Vetrano, Edoardo Tringali, Luca Di Lullo, Marcello Napoli, Gaetano La Manna, Giuseppe Cianciolo","doi":"10.1159/000541876","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that high blood pressure (BP) is an independent risk factor for disease progression in both adult and pediatric patients with kidney disorders and progressive decline in kidney function can conversely lead to worsening BP control.</p><p><strong>Summary: </strong>Hypertension in CKD is not only associated with GFR loss, but increases cardiovascular risk, which is the leading source of mortality and morbidity in this population. Given this complex relationship between hypertension, CKD, and CVD, an optimal management of BP in CKD is mandatory to break an established vicious pathophysiological cycle that leads to adverse outcomes.</p><p><strong>Key messages: </strong>New promising molecules for the treatment of CKD, with interesting mechanisms, particularly regarding their pathophysiological interactions with arterial hypertension, are available or under development and in the very next future they may change the way we treat high BP in CKD patients.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"581-587"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541876","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that high blood pressure (BP) is an independent risk factor for disease progression in both adult and pediatric patients with kidney disorders and progressive decline in kidney function can conversely lead to worsening BP control.

Summary: Hypertension in CKD is not only associated with GFR loss, but increases cardiovascular risk, which is the leading source of mortality and morbidity in this population. Given this complex relationship between hypertension, CKD, and CVD, an optimal management of BP in CKD is mandatory to break an established vicious pathophysiological cycle that leads to adverse outcomes.

Key messages: New promising molecules for the treatment of CKD, with interesting mechanisms, particularly regarding their pathophysiological interactions with arterial hypertension, are available or under development and in the very next future they may change the way we treat high BP in CKD patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心血管疾病和肾脏疾病中的高血压,最新趋势:将两种疾病视为一种。
背景:高血压和慢性肾脏病(CKD)是密切相关的病理生理状态,因此高血压是成人和儿童肾脏疾病患者病情恶化的独立危险因素,而肾功能的逐渐衰退又会导致血压控制恶化。鉴于高血压、慢性肾脏病和心血管疾病之间的复杂关系,必须对慢性肾脏病患者的血压进行优化管理,以打破导致不良后果的恶性病理生理循环:治疗慢性肾脏病的新分子前景广阔,其机制令人感兴趣,尤其是它们与动脉高血压之间的病理生理相互作用,这些新分子已经上市或正在开发之中,在不久的将来,它们可能会改变我们治疗慢性肾脏病患者高血压的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
期刊最新文献
A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data. EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. Cardiorenal disease and heart failure with preserved ejection fraction: Two sides of the same coin. Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1